New, exciting developments in experimental therapies in the early 21st century

European Journal of Pharmacology

Volumn 625, Issue 1-3, 2009, Pages 1-5

  Los, Marek ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BioApplications Enterprises Winnipeg   (Canada)

Author keywords

Bystander effect; DNMT; Epidermal growth factor; HDAC; Her2 neu; RAGE; S100A8 A9; SDF 1; Single nucleotide polymorphism

Indexed keywords

APOPTIN; CADHERIN; CALGRANULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; RANPIRNASE; STROMAL CELL DERIVED FACTOR 1; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOINFORMATICS; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER THERAPY; DNA REPAIR; DRUG SYNTHESIS; DRUG TARGETING; EPIGENETICS; GENETIC VARIABILITY; HUMAN; IMMUNOREGULATION; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 71749102419     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.008     Document Type: Review

References (37)

1. Ande S.R., Chen J., and Maddika S. The ubiquitin pathway: An emerging drug target in cancer therapy. Eur. J. Pharmacol. 265 (2009) 199-205 (this volume)
2. Ardelt W., Ardelt B., and Darzynkiewicz Z. Ribonucleases as potential modalities in anticancer therapy. Eur. J. Pharmacol. 265 (2009) 181-189 (this volume)
3. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997) 730-737
4. Booy E.P., Johar D., Maddika S., Pirzada H., Sahib M.M., Gehrke I., Loewen S.D., Louis S.D., Kadkhoda K., Mowat M., and Los M. Monoclonal and bispecific antibodies as novel therapeutics. Arch. Immunol. Ther. Exp. 54 (2006) 1-17
5. Borghaei H., Smith M.R., and Campbell K.S. Immunotheraphy of Cancer. Eur. J. Pharmacol. 265 (2009) 41-54 (this issue)
6. Burdak-Rothkamm S., and Prise K.M. New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and nontargeted cells. Eur. J. Pharmacol. 265 (2009) 151-155 (this issue)
7. Christoffersen T., Guren T.K., Garm Spindler K.-L., Dahl O., Lønning E., and Tore Gjertsen B. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. Eur. J. Pharmacol. 265 (2009) 6-22 (this volume)
8. Darzynkiewicz Z., Traganos F., and Wlodkowic D. Impaired DNA Damage Response - an Achilles' Heel Sensitizing Cancer to Chemotherapy and Radiotherapy. Eur. J. Pharmacol. 265 (2009) 143-150 (this issue)
9. Devemy E., and Blaschuk O.W. Cadherins as novel targets for anti-cancer therapy. Eur. J. Pharmacol. 265 (2009) 195-198 (this volume)
10. Gadji M., Tsanaclis Crous A.M., Fortin D., Krcek J., Torchia M., Mai S., Drouin R., and Klonisch T. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Eur. J. Pharmacol. 265 (2009) 23-30 (this volume)
11. Ghavami S., Asoodeh A., Klonisch T., Halayko A.J., Kadkhoda K., Kroczak T.J., Gibson S.B., Booy E.P., Naderi-Manesh H., and Los M. Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J. Cell. Mol. Med. 12 (2008) 1005-1022
12. Ghavami S., Chitayat S., Hashemi M., Eshraghi M., Chazin W.J., Halayko A.J., and Kerkhoff C. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur. J. Pharmacol. 265 (2009) 73-83 (this volume)
13. Ghavami S., Kerkhoff C., Chazin W.J., Kadkhoda K., Xiao W., Zuse A., Hashemi M., Eshraghi M., Schulze-Osthoff K., Klonisch T., and Los M. S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim. Biophys. Acta 1783 (2008) 297-311
14. Ghavami S., Rashedi I., Dattilo B.M., Eshraghi M., Chazin W.J., Hashemi M., Wesselborg S., Kerkhoff C., and Los M. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J. Leukoc. Biol. 83 (2008) 1484-1492
15. Healy S.J.M., Gorman A.M., Mousavi-Shafaei P., Gupta S., and Samali A. Targeting the endoplasmic reticulum-stress response as an anti-cancer strategy. Eur. J. Pharmacol. 265 (2009) 234-246 (this volume)
16. Holoch P., and Griffith T.S. TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. Eur. J. Pharmacol. 265 (2009) 63-72 (this volume)
17. Hombach-Klonisch S., Paranjothy T., Wiechec E., Pocar P., Mustafa T., Seifert A., Zahl C., Gerlach K.L., Biermann K., Steger K., Hoang-Vu C., Schulze-Osthoff K., and Los M. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch. Immunol. Ther. Exp. 56 (2008) 165-180
18. Johnston J.B., Navaratnam S., Pitz M.W., Maniate J.M., Wiechec E., Baust H., Gingerich J., Skliris G.P., Murphy L.C., and Los M. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem. 13 (2006) 3483-3492
19. Klonisch T., Wiechec E., Hombach-Klonisch S., Ande S.R., Wesselborg S., Schulze-Osthoff K., and Los M. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 14 (2008) 450-460
20. Kristensen L.S., Nielsen H.M., and Hansen L.L. Epigenetics and cancer treatment. Eur. J. Pharmacol. 265 (2009) 131-142 (this volume)
21. Krzemieniecki K., Szpyt E., Rashedi I., Gawron K., and Los M. Targeting of solid tumors and blood malignancies by antibody-based therapies. Centr. Eur. J. Biol. 1 (2006) 167-182
22. Mackiewicz J., and Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur. J. Pharmacol. 265 (2009) 84-89 (this volume)
23. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., Eshraghi M., Manda K.D., Wiechec E., and Los M. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist. Updat. 10 (2007) 13-29
24. Maddika S., Ande S.R., Wiechec E., Hansen L.L., Wesselborg S., and Los M. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J. Cell Sci. 121 (2008) 979-988
25. Maddika S., Wiechec E., Ande S.R., Poon I.K., Fischer U., Wesselborg S., Jans D.A., Schulze-Osthoff K., and Los M. Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin. Oncogene 27 (2008) 3060-3065
26. Mandal S., Moudgil M., and Mandal S. Rational drug design. Eur. J. Pharmacol. 265 (2009) 90-100 (this volume)
27. McFarlane A., Orriss G.L., and Stetefeld J. The use of coiled-coil proteins in drug delivery systems. Eur. J. Pharmacol. 265 (2009) 101-107 (this volume)
28. Noteborn M.H.M. Proteins selectively killing tumor cells. Eur. J. Pharmacol. 265 (2009) 165-173 (this volume)
29. Onkal R., and Djamgoz M.B.A. Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer. Eur. J. Pharmacol. 265 (2009) 206-219 (this volume)
30. Ratajczak M., Maksym B.R., Grymula K., Tarnowska J., Wysoczynski M., Liu R., Ratajczak J., and Kucia M. The Role of Stromal Derived Factor-1 - CXCR7 Axis in Development and Cancer. Eur. J. Pharmacol. 265 (2009) 31-40 (this volume)
31. Rzeszowska-Wolny J., Przybyszewski W.M., and Widel M. Ionizing radiation-induced bystander effects, potential targets for modulation of radiotherapy. Eur. J. Pharmacol. 265 (2009) 156-164 (this volume)
32. Schweizer F. Cationic amphiphilic peptides (CAPs) with cancer-selective toxicity. Eur. J. Pharmacol. 265 (2009) 190-194 (this volume)
33. Solomon R.V., and Lee H. Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur. J. Pharmacol. 265 (2009) 220-233 (this volume)
34. Swierniak A., Kimmel M., and Smieja J. Mathematical modeling as a tool for planning anticancer therapy. Eur. J. Pharmacol. 265 (2009) 108-121 (this volume)
35. Wagstaff K.M., and Jans D.A. Nuclear drug delivery to target tumour cells. Eur. J. Pharmacol. 265 (2009) 174-180 (this volume)
36. Wiechec E., and Hansen L.L. The effect of genetic variability on drug response in conventional breast cancer treatment. Eur. J. Pharmacol. 265 (2009) 122-130 (this volume)
37. Zoller F., Eisenhut M., Haberkorn U., and Mier V. Endoradiotherapy in cancer treatment - basic concepts and future trends. Eur. J. Pharmacol. 265 (2009) 55-62 (this volume)